Xofigo

Xofigo (Radium Ra 223 Dichloride) is a radiopharmaceutical used to treat bone metastases in prostate cancer. Administered via intravenous infusion, it targets bone tissue to reduce pain and slow progression. Suitable for patients with symptomatic bone metastases. Short-term monitoring recommended after treatment.

Xofigo is used to treat bone metastases in patients with castration-resistant prostate cancer. It works by targeting areas of bone growth with targeted radiation, helping to relieve pain and slow the spread of cancer to bones. This treatment is typically considered when other therapies are no longer effective. Patients often seek options like Xofigo to manage symptoms and improve quality of life.

Xofigo is designed to reduce bone pain associated with metastases by delivering radiation directly to affected areas. Patients may experience temporary relief from discomfort and improved mobility. Common effects include mild fatigue and digestive changes, which are typically short-lived. Regular monitoring helps manage any side effects.

Xofigo should be handled by healthcare professionals in a controlled medical setting. Patients may need to avoid close contact with others for a short period after treatment to minimize radiation exposure. Hydration and frequent urination help reduce bladder exposure. Pregnant individuals should avoid handling Xofigo due to radiation risks.

Xofigo may interact with other radiopharmaceuticals or chemotherapy agents, so concurrent treatments should be carefully coordinated. Patients undergoing external beam radiation therapy may need to pause Xofigo temporarily. Blood thinners and bone-strengthening medications may require adjustment during treatment. Always inform your healthcare provider about all medications being taken.